27 March 2017
News and Views
Links and Services
The latest issue of the Clinical Gastroenterology & Hepatology assesses the relationships between deep remission and other outcomes among patients who received adalimumab.
Patients with moderate to severe ileocolonic Crohn's disease (CD) who received adalimumab inducti
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors